z-logo
Premium
Immunophenotypic aspects of cylindroma and nodular hidradenoma
Author(s) -
Canedo T,
De Almeida MP,
Cuzzi T,
RamoseSilva M
Publication year - 2010
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2009.03398.x
Subject(s) - cylindroma , cd15 , hidradenoma , pathology , histogenesis , medicine , immunohistochemistry , biology , cd34 , stem cell , genetics
Background  Some adnexal tumours have many controversies about their histogenesis. Objectives  To evaluate the eccrine and/or apocrine differentiation phenotype in cases of cylindroma and clear cell hidradenoma with CD15 and p63 antibodies. Methodology  Slides and blocks of six cases of cylindroma and seven cases of nodular hidradenoma (clear cells) were analyzed by the technique of immunohistochemistry with CD15 and p63 antibodies. Results  In all cases of cylindroma we obtained negative results for CD15 antibody and positive for p63 antibody. In five of seven cases of nodular hidradenoma (clear cell), we could easily observe clear cells between 20% and 50% of tumour cells. In the two other cases, cystic lesions were present and occasional clear cells could be seen. The reaction with CD15 antibody was positive in granular and cytoplasmic pattern in six of seven cases, especially in cells with suggestive clear cytoplasm in lower proportion than this clear cells could be seen in haematoxylin and eosin. The positivity for p63 antibody, nuclear pattern, was observed in six of seven cases, in the major part of tumour cells. In only one case, the positivity was in 20% of cells. Limitation  Samples are in small number because these are relatively rare tumours. Conclusions  The present study suggests eccrine origin for both tumours: cylindroma and clear cell hidradenoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here